Clinical trials: Diabetes, Type 1
Type 2 Diabetes
A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes
The aim of this trial is to compare the efficacy and safety of HR17031 versus INS068 and SHR20004 in subjects with type 2 diabetes.
- Trial name
- NCT05333835
- Testing
- HR17031 injection, INS068 injection, SHR20004 injection
- Where
- China
- Volunteers
- 455 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced/Metastatic Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors
This study is a multi-center, open-label, dose-escalation, dose-expansion, and cohort-expansion first-in-human Phase 1/2 study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of…
- Trial name
- NCT07857135
- Testing
- SYS6088, Regorafenib, Ivonescimab
- Volunteers
- 140 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Diabetes Mellitus, Type 1
Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions
The study is an open-label, randomized, two-period crossover study. Up to one hundred and twenty (120) subjects with type 1 diabetes mellitus (T1DM) who use the MiniMed paradigm insulin pump, who meet the inclusion/exclusion…
- Trial name
- Daily Life (NCT01283425)
- Testing
- InsuPatch
- Where
- 8 sites in United States, Israel
- Volunteers
- 147 people
- Sponsor
- Insuline Medical Ltd.
Metastatic Melanoma
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
- Trial name
- NCT03445533
- Testing
- Ipilimumab, Tilsotolimod with Ipilimumab
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 481 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Diabetes Mellitus
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast…
- Trial name
- NCT00046501
- Testing
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes
The purpose of this study is to examine the efficacy and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime insulin therapy in patients with type 1…
- Trial name
- IOOZ (NCT00487240)
- Testing
- Insulin Lispro Protamine Suspension, Insulin Levemir
- Where
- 28 sites in United States, Argentina and 7 more
- Volunteers
- 387 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes
This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.
- Trial name
- NCT07052292
- Testing
- DuraTouch®
- Where
- 11 sites in Poland
- Volunteers
- 128 people
- Sponsor
- Novo Nordisk A/S
Hypoglycemia, Type 1 Diabetes
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
This research study will investigate whether dasiglucagon as a rescue therapy for participants under 6 years of age works and is safe to use.
- Trial name
- NCT05378672
- Testing
- Dasiglucagon
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Zealand Pharma
Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
This trial is conducted in the United States of America (USA) and Canada. The aim of this research is to compare the efficacy (reduction in HbA1c and blood glucose) and pulmonary safety (pulmonary function, chest x-rays) of…
- Trial name
- NCT00322257
- Testing
- inhaled human insulin, insulin detemir, insulin aspart
- Where
- 96 sites in United States, Canada
- Volunteers
- 596 people
- Sponsor
- Novo Nordisk A/S
Diabetic Foot Ulcer
A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers
This prospective, multi-center, randomized, controlled modified platform Trial compares Purified Native Type 1 Collagen Extracellular Matrix with Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care versus…
- Trial name
- PREPARE (NCT06618612)
- Testing
- Standard of Care, PuraPly AM, PuraPly XT
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Organogenesis
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Three Lancing Devices Regarding Capillary Blood Volume and Lancing Pain Intensity.
A randomized single-blind study with the use of three lancing devices equipped with personal lancets. Every device will be studied for three lancet sizes: 28G, 30G, and 33G with the minimum and maximum puncture depth setting.
- Trial name
- NCT03479619
- Testing
- Lancing device A, Lancing device B, Lancing device C
- Where
- Poland
- Volunteers
- 90 people
- Sponsor
- HTL-Strefa S.A.
Type 1 Diabetes Mellitus
Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients
Primary Objective: To assess the safety of SAR341402 and NovoLog® when used in external insulin pumps in terms of the number of patients with infusion set occlusions.
- Trial name
- NCT03436498
- Testing
- Insulin aspart SAR341402, Insulin aspart
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Sanofi
Diabetes (Insulin-requiring, Type 1 or Type 2), Pancreatogenic Diabetes Mellitus
DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients
A Multicenter, Open label, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen DIA:CONN P8 in patients with Type 1, Type 2 or Pancreatogenic Diabetes Mellitus under Multiple Dose…
- Trial name
- NCT06406439
- Testing
- Smart Insulin Pen, Injection of bolus insulin via conventional therapy using insulin pen
- Where
- 9 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- G2e Co., Ltd
Type 1 Diabetes Mellitus
Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus
Primary Objective: To assess the safety and tolerability of two dose levels of a new insulin glargine formulation in a once-daily multiple dosing regimen Secondary Objective: To compare the pharmacokinetic and pharmacodynamic…
- Trial name
- NCT01349855
- Testing
- Insulin glargine HOE901
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, complications in diabetic subjects in Asia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00839878)
- Testing
- No treatment given
- Where
- Bangladesh
- Volunteers
- 2,092 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)
To assess the safety and performance of the Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm in adults with type…
- Trial name
- IDE2 (NCT03064906)
- Testing
- Insulet AP (artificial pancreas) System
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Insulet Corporation
Type 2 Diabetes Mellitus, Hepatic Impairment
Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)
This is a study to assess the pharmacokinetics and safety of ertugliflozin (MK-8835, PF-04971729) in participants with hepatic impairment versus healthy participants.
- Trial name
- NCT02115347
- Testing
- Ertugliflozin 15 mg
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type II Diabetes Mellitus
A Clinical Trial to Evaluate the Food Effect of CKD-379
A clinical trial to evaluate the food effect of CKD-379
- Trial name
- CKD-379 (NCT06652971)
- Testing
- CKD-379
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 1 Diabetes
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®
This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric subjects utilizing Fiasp (insulin aspart injection) in a home setting.
- Trial name
- NCT05224258
- Testing
- MiniMed 780G System
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 240 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus
The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for up to four (4) months.
- Trial name
- NCT03162926
- Testing
- VC-02 Combination Product (aka PEC-Direct)
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- ViaCyte
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.